Sugarloaf Wealth Management’s NovoCure NVCR Stock Holding History

Sugarloaf Wealth Management’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-300	Closed	-$12.4K	–	695
2023 Q2	$12.4K	Hold	300	–	–	﹤0.01%	445
2023 Q1	$18K	Hold	300	–	–	﹤0.01%	405
2022 Q4	$22K	Sell	300 -100	-25%	-$7.52K	0.01%	396
2022 Q3	$31K	Hold	400	–	–	0.01%	359
2022 Q2	$20K	Buy	400 +100	+33%	+$7.53K	0.01%	412
2022 Q1	$25K	Hold	300	–	–	0.01%	378
2021 Q4	$23K	Hold	300	–	–	0.01%	404
2021 Q3	$35K	Hold	300	–	–	0.01%	331
2021 Q2	$67K	Hold	300	–	–	0.02%	240
2021 Q1	$40	Hold	300	–	–	0.01%	305
2020 Q4	$52K	Hold	300	–	–	0.02%	248
2020 Q3	$33K	Hold	300	–	–	0.01%	294
2020 Q2	$18K	Hold	300	–	–	0.01%	369
2020 Q1	$20K	Buy	+300	New	+$23.7K	0.01%	334

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return

Sugarloaf Wealth Management's NVCR Position: Q3 2023 in Review

Sugarloaf Wealth Management sold out of NovoCure (NVCR) in Q3 2023, closing a stake of 300 shares — an estimated $12.4K sold.

Sugarloaf Wealth Management first reported a position in NVCR in Q1 2020 and held it in 14 quarters. The position peaked at $67K in Q2 2021. 226 funds tracked by Wall St. Rank hold NVCR as of Q3 2023.

Sugarloaf Wealth Management reported no remaining NovoCure position as of Q3 2023 after selling out during the quarter.
Sugarloaf Wealth Management sold 300 NovoCure shares in Q3 2023, an estimated $12.4K.
Sugarloaf Wealth Management first reported a position in NovoCure in Q1 2020 and held it in 14 quarters.
Sugarloaf Wealth Management's NovoCure position peaked at $67K in Q2 2021.
226 funds tracked by Wall St. Rank held NovoCure as of Q3 2023.

Based on Sugarloaf Wealth Management's 13F filing for Q3 2023, filed 13 Nov 2023.